TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical announced the approval for drug registration of one of its subsidiaries, which marks a significant milestone in its operational capabilities. This approval is expected to enhance the company’s market position and could have positive implications for its stakeholders, reflecting the company’s ongoing commitment to expanding its pharmaceutical offerings.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the pharmaceutical industry. It is listed on the Stock Exchange of Hong Kong and is involved in the development, manufacturing, and distribution of pharmaceutical products.
Average Trading Volume: 10,767,897
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.78B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.